Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1226208 | 1.00 | TSHR (0.50) | TSHRCYP2A6ALDH1A1CA12CA2 | |
| SCHEMBL1225840 | 1.00 | TSHR (0.50) | TSHRCYP2A6ALDH1A1CA12CA2 | |
| SCHEMBL10686501 | 0.87 | TSHR (0.39) | TSHRCYP2A6ALDH1A1CYP19A1MAOA | |
| SCHEMBL10686497 | 0.87 | TSHR (0.39) | TSHRCYP2A6ALDH1A1CYP19A1MAOA | |
| SCHEMBL10356459 | 0.83 | CHRM2 (0.43) | TSHRCYP2A6 | |
| SCHEMBL10689277 | 0.83 | CHRM2 (0.43) | TSHRCYP2A6 | |
| SCHEMBL28935583 | 0.83 | MAOA (0.39) | CYP2A6ALDH1A1CA12CA2CA3 | |
| SCHEMBL10549395 | 0.82 | HRH3 (0.36) | TSHRCYP2A6ALDH1A1CYP19A1MAOA | |
| SCHEMBL7508064 | 0.80 | CHRM2 (0.41) | TSHRCYP2A6 | |
| SCHEMBL8046424 | 0.80 | CHRM2 (0.41) | TSHRCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11710854-B2 | Functional epoxides in catalyst-based electrolyte compositions for Li-ion batteries | ENEVATE CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220140392-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-05-05 | — | — | US | disclosed |
| CN-109593069-A | A kind of method of biocatalysis synthesis 4- substituted oxazolidine ketone compound | 遵义医学院 | 2019-04-09 | — | — | CN | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2427444-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9018211-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-6770659-B2 | Benzoyl piperidine compounds | SK CORPORATION (KR) | 2004-08-03 | — | — | US | disclosed |
| US-20040116464-A1 | Aryl-ethanolamine derivatives as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-17 | — | — | US | disclosed |
| WO-2004022568-A1 | ARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-18 | — | — | WO | disclosed |
| EP-1047695-B1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2004018423-A1 | NEW BENZOYL PIPERIDINE COMPOUNDS | SK CORPORATION (KR) | 2004-03-04 | — | — | WO | disclosed |
| US-20040044033-A1 | New benzoyl piperidine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2004-03-04 | — | — | US | disclosed |
| US-6291475-B1 | 3,7-DIAZABICYCLO(3.3.1)NONANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| EP-1047695-A1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999031100-A1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | TSHR 3008/4885CYP2A6 990/4885ALDH1A1 943/4885 |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | TSHR 264/4885CYP2A6 1294/4885ALDH1A1 683/4885 |
| US-20040044033-A1 | New benzoyl piperidine compounds | GABRE, GRIN2C, GRIN1 | TSHR 3719/4885CYP2A6 2998/4885ALDH1A1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.